Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profile of bacterial meningitis pathogens circulating in a cohort of school children in Côte d'Ivoire using 16S rRNA gene sequencing.

BMC infectious diseases·2026
Same author

Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts.

Nature immunology·2026
Same author

An update on recent developments in the drug treatment of tuberculous meningitis.

Expert opinion on pharmacotherapy·2026
Same author

Predicting trajectories of illness using RNA velocity of whole blood.

Nature communications·2026
Same author

Contribution of cytotoxic CD8 T cells, neutrophils and type 1 interferon signaling to hyperinflammation in HIV-associated TB meningitis.

bioRxiv : the preprint server for biology·2026
Same author

PET-CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort study.

The Lancet. Respiratory medicine·2026

Related Experiment Videos

Eliminating latent tuberculosis.

Douglas B Young1, Hannah P Gideon, Robert J Wilkinson

  • 1National Institute for Medical Research, Mill Hill, London, NW7 1AA, UK. dyoung@nimr.mrc.ac.uk

Trends in Microbiology
|April 21, 2009
PubMed
Summary
This summary is machine-generated.

Latent tuberculosis, often asymptomatic, presents a spectrum from bacillary elimination to subclinical disease. Understanding this heterogeneity in bacteria and host immunity can reveal new diagnostic and therapeutic strategies for tuberculosis.

Related Experiment Videos

Area of Science:

  • Infectious Diseases
  • Immunology
  • Microbiology

Background:

  • Tuberculosis (TB) is a leading global cause of bacterial death.
  • Latent TB infection (LTBI) is diagnosed via immune response, not bacterial presence.
  • Current understanding of LTBI may oversimplify a complex spectrum of disease states.

Purpose of the Study:

  • To challenge the monolithic view of latent tuberculosis.
  • To highlight the heterogeneity of bacillary and host immune responses in LTBI.
  • To explore novel therapeutic and diagnostic avenues based on this heterogeneity.

Main Methods:

  • Review of recent research on Mycobacterium tuberculosis physiology.
  • Analysis of host immune responses in individuals with varying degrees of TB infection.
  • Synthesis of findings to propose a spectrum model for latent TB.

Main Results:

  • Latent TB likely encompasses a range from bacillus elimination to subclinical disease.
  • Significant variability exists in both bacterial states and host immune reactions.
  • This heterogeneity suggests current diagnostic and treatment approaches may be insufficient.

Conclusions:

  • The term 'latent tuberculosis' may be too broad and mask important distinctions.
  • Recognizing the spectrum of LTBI is crucial for developing targeted interventions.
  • Further research into bacillary and host heterogeneity can drive innovation in TB diagnostics and therapeutics.